Polymersomes for the removal of amyloid beta and / or tau proteins

Polymersomes functionalized with LRP-1 ligands enhance the transport and clearance of amyloid-β and tau proteins across the blood-brain barrier, addressing the reduced expression of LRP-1 in endothelial cells and providing therapeutic benefits for neurodegenerative diseases.

JP2024543902AInactive Publication Date: 2024-11-26UCL BUSINESS LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024531149
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-24
Filing Date
2022-11-23
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The impaired transport and clearance of amyloid-β and tau proteins across the blood-brain barrier, mediated by low-density lipoprotein receptor-related protein 1 (LRP-1), contribute to neurodegenerative diseases such as Alzheimer's and Parkinson's, due to reduced expression of LRP-1 in brain endothelial cells.

Method used

Synthetic polymer vesicles (polymersomes) functionalized with LRP-1 ligands are used to stabilize and promote the transport of LRP-1 across endothelial cells, enhancing its expression and facilitating the removal of amyloid-β and tau proteins from the brain.

Benefits of technology

The polymersomes increase LRP-1-mediated clearance of amyloid-β and tau proteins, reducing their levels in the brain and providing neuroprotective effects, as demonstrated by in vivo studies in Alzheimer's disease models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543902000008
    Figure 2024543902000008
  • Figure 2024543902000009
    Figure 2024543902000009
  • Figure 2024543902000010
    Figure 2024543902000010
Patent Text Reader

Abstract

The present invention is directed to nanoparticles or microparticles that bind to the surface of endothelial cells, e.g., brain endothelial cells, for use in a method of reducing amyloid-β and / or tau levels in an organ (e.g., the brain) of a patient in need thereof, wherein said nanoparticles or microparticles comprise on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of said endothelial cells, thereby facilitating the transport of LRP-1 across said endothelial cells. The present invention is further directed to such nanoparticles or microparticles themselves, further comprising an encapsulated drug selected from an anti-Alzheimer's drug, and / or a drug useful for reducing amyloid-β and / or tau levels or inhibiting the formation of amyloid-β and / or tau, as well as pharmaceutical compositions comprising a plurality of such nanoparticles or microparticles.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention is directed to nanoparticles or microparticles that bind to the surface of endothelial cells (e.g., brain endothelial cells) for use in a method of reducing amyloid-β and / or tau levels in an organ (e.g., the brain) of a patient in need thereof, wherein said nanoparticles or microparticles comprise on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of said endothelial cells, thereby facilitating the transport of LRP-1 across said endothelial cells. The present invention is further directed to such nanoparticles or microparticles themselves, further comprising an encapsulated drug selected from an anti-Alzheimer's drug, and / or a drug useful for reducing amyloid-β and / or tau levels or inhibiting the formation of amyloid-β and / or tau, as well as pharmaceutical compositions comprising a plurality of such nanoparticles or microparticles. [Background technology]

[0002] 2. Background of the Invention Amyloid-β (Aβ) is a heterogeneous mixture of small peptides (37–43 amino acids) resulting from sequential cleavage of the amyloid precursor protein (APP). Aβ monomers spontaneously aggregate into neurotoxic aggregates known as oligomers and fibrils, especially in the brain. Tau proteins control neuronal microtubules and, when they become hyperphosphorylated, assemble into insoluble structures known as neurofibrillary tangles. Impaired transport of Aβ and / or tau proteins across the blood-brain barrier (BBB), as well as their reduced clearance from the brain, contribute to neurodegenerative and vascular pathologies such as Alzheimer's disease, Parkinson's disease, some dementias, and cerebrovascular disorders. At the BBB, efflux transport of Aβ and tau is mediated by low-density receptor-related protein (LRP-1). LRP-1 is a multifunctional signaling receptor that binds various ligands, including Aβ and tau, directly interacts with them in endothelial cells (e.g., brain endothelial cells at the BBB), and rapidly initiates their clearance from organs (e.g., the brain) to the blood. Several studies have reported that LRP-1 expression is decreased in brain endothelial cells at the BBB during normal aging and further decreased in AD patients, which promotes the accumulation of Aβ and tau in the brain. Therefore, strategies to regulate the levels of LRP-1 in cerebral blood vessels and restore LRP-1-mediated clearance of Aβ and tau from the brain are promising approaches for the treatment of neurodegenerative diseases such as Alzheimer's disease.

[0003] LRP-1 is a member of the LDL receptor family, which plays diverse roles in various biological processes, including lipoprotein metabolism, protease degradation, activation of lysosomal enzymes, and intracellular entry of bacterial toxins and viruses. Deletion of the LRP-1 gene led to lethality in mice, revealing a critical, but so far unexplored, role in development. Tissue-specific gene deletion studies revealed important contributions of LRP-1 in the vasculature, central nervous system, macrophages, and adipocytes.

[0004] LRP-1 has been reported to bind more than 40 ligands and undergo rapid endocytosis with a half-life of less than 30 seconds (Lillis et al., Physiool. Rev., 2008, 88, 887-918). Endocytosed LRP-1 can then be transported across endothelial cells via the endolysosomal network and subsequently presented on the opposite side of the plasma membrane from its original location via exocytosis. This entire process is known as transcytosis. Alternatively, internalized LRP-1 can be marked for degradation in lysosomes.

[0005] It would therefore be desirable to develop pharmaceutical agents that can modulate expression of LRP-1 in endothelial cells (e.g., brain endothelial cells) in such a way as to maximize LRP-1-mediated clearance of amyloid-β from organs such as the brain. The present invention addresses this problem and provides pharmaceutical agents useful for this purpose. Summary of the Invention

[0006] The inventors have surprisingly found that by using synthetic polymer vesicles (polymersomes) composed of copolymers functionalized with LRP-1 ligands, it is possible to inhibit the degradation of LRP-1 and instead promote the transport of LRP-1 across endothelial cells (e.g. brain endothelial cells) from the apical (blood) side to the basal (organ, e.g. brain) side via a specific mechanism, whereby LRP-1 is transported across cells by transcytosis in a structure stabilized by syndapin-2. As a result, LRP-1-mediated removal of amyloid-β and / or tau proteins from the basal side to the apical side of endothelial cells can be increased.

[0007] Furthermore, it has been found that LRP-1 expression levels in endothelial cells (e.g., brain endothelial cells) are sensitive to structural features of the nanoparticles or microparticles, such as ligand type and density, particle surface area, and steric potential between the nanoparticles or microparticles and the endothelial cell surface. Thus, the present invention also provides an algorithm for optimizing nanoparticles or microparticles to provide the highest possible LRP-1 expression levels, and thus the most efficient clearance of amyloid-β and / or tau.

[0008] Moreover, nanoparticles or microparticles are particularly attractive targets for the activation of LRP-1 transcytosis, since they can be further loaded with relevant drugs to address other mechanisms involved in the pathology of related diseases caused and / or associated with amyloid beta and / or tau. For example, nanoparticles or microparticles can be further loaded with relevant drugs to address other mechanisms involved in the pathology of Alzheimer's disease, such as inflammation, or cerebrovascular disease. Such nanoparticles or microparticles allow not only the removal of amyloid-beta and / or tau across the BBB, but also the management of other signaling cascades triggered in the brain in neurodegenerative diseases such as Alzheimer's disease.

[0009] Thus, the present invention provides endothelial cell surface-binding nanoparticles or microparticles for use in a method for reducing amyloid-β and / or tau levels in an organ of a patient in need thereof, wherein the nanoparticles or microparticles comprise on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of the endothelial cells, thereby facilitating transport of LRP-1 across the endothelial cells. For example, brain endothelial cell surface-binding nanoparticles or microparticles for use in a method for reducing amyloid-β and / or tau levels in the brain of a patient in need thereof are provided, wherein the nanoparticles or microparticles comprise on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of the endothelial cells, thereby facilitating transport of LRP-1 across the endothelial cells.

[0010] The present invention also provides a pharmaceutical composition for use in a method for reducing amyloid-β and / or tau levels in an organ of a patient in need thereof, wherein said pharmaceutical composition comprises a plurality of nanoparticles or microparticles as defined herein and one or more pharma- ceutically acceptable excipients. In a preferred embodiment, the organ is the brain.

[0011] The present invention also provides a method for reducing amyloid-β and / or tau levels in an organ of a patient in need thereof, comprising administering to the patient a therapeutically effective amount of nanoparticles or microparticles comprising on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of endothelial cells, thereby facilitating transport of LRP-1 across the endothelial cells. In a preferred embodiment, the method is for reducing amyloid-β and / or tau levels in the brain of a patient in need thereof, comprising administering to the patient a therapeutically effective amount of nanoparticles or microparticles comprising on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of brain endothelial cells, thereby facilitating transport of LRP-1 across the brain endothelial cells.

[0012] The present invention also provides the use of nanoparticles or microparticles for the manufacture of a medicament for reducing amyloid-β and / or tau levels in an organ of a patient in need thereof, wherein said nanoparticles or microparticles comprise on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of endothelial cells, thereby facilitating transport of LRP-1 across said endothelial cells. In a preferred embodiment, the organ is the brain and the endothelial cells are brain endothelial cells.

[0013] The present invention also provides: (i) a ligand species on the outer surface of an endothelial cell that is capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of the endothelial cell, thereby facilitating transport of LRP-1 across the endothelial cell; and (ii) an encapsulated drug selected from anti-Alzheimer's drugs and / or drugs useful for reducing levels of amyloid-β and / or tau or inhibiting the formation of amyloid-β and / or tau; wherein preferably the drug is selected from donepezil, galantamine, rivastigmine, and memantine. In a preferred embodiment, the endothelial cells are brain endothelial cells.

[0014] The present invention also provides a pharmaceutical composition comprising a plurality of nanoparticles or microparticles according to the present invention and one or more pharma- ceutically acceptable excipients. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 shows the particle size distribution of AP22-POs measured by dynamic light scattering (a) and a transmission electron micrograph of AP22-POs (staining agent: phosphotungstic acid (PTA)) (b). [Diagram 2] Figure 2 is a box plot showing LRP-1 expression in polarized mouse brain endothelial cells normalized to loading control (GAPDH) both before and after treatment with AP22-POs for 2 hours. *=P<0.05, Student's T-test (n=6). [Diagram 3] Figure 3 shows basolateral to apical transport of amyloid-β across polarized brain endothelial cells pretreated for 2 hours with AP22-POs, in which the AP22-POs was applied to either the apical (upper circle at each time point) or basolateral (lower circle at each time point) side of the membrane. Data are presented as mean ± standard deviation. [Figure 4] Figure 4 shows the effect of polymersome administration to Alzheimer's disease mice (groups 1-3) and healthy mice (groups 4-5) on amyloid-β and tau protein levels. (A) shows western blots of amyloid-β and tau protein for each cohort of mice, in addition to actin as a control. (B) shows the amyloid-β concentration for each cohort in graph form. (C) shows the tau concentration for each cohort in graph form. n=3 for all cohorts. [Diagram 5]Figure 5 shows the effect of polymersome administration to Alzheimer's disease mice (groups 1-3) and healthy mice (groups 4-5) on the levels of liver function markers ALT (A), AST (B), and ALP (C). n=3 for all cohorts. [Figure 6] Figure 6 shows the effect of polymersome administration to Alzheimer's disease mice (groups 1-3) and healthy mice (groups 4-5) on the levels of renal function markers BUN (A), Cr (B), and ALP (C). n=3 for all cohorts. [Figure 7] FIG. 7 shows plasma amyloid beta and tau concentrations over time following administration of polymersomes to Alzheimer's disease mice. [Figure 8] FIG. 8 shows PET / CT scans of an APP-PS1 Alzheimer's disease model mouse (top), an APP-PS1 Alzheimer's disease model mouse treated with polymersomes (middle), and a healthy mouse (bottom), all injected with [18F](E)-4-(2-(6-(2-(2-(2-18F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzamine to label amyloid-β. The scans show that the amount of amyloid beta present in the brain was significantly reduced in the group of animals treated with polymersomes. [Figure 9] FIG. 9 shows a heat map of total ligand / LRP-1 binding energy in brain endothelial cells as a function of LRP-1 receptor density, nanoparticle / microparticle radius, and ligand number. The black / darkest areas of the graph indicate stronger than optimal affinity of the nanoparticle / microparticle to the target cells, resulting in predominantly endocytosis of LRP-1 receptors in brain endothelial cells. The gray areas of the graph indicate weaker than optimal binding of the nanoparticle / microparticle to the target cells. The white / lightest areas of the graph indicate optimal levels of nanoparticle / microparticle binding to LRP-1 on the surface of brain endothelial cells, which promotes transcytosis of LRP-1 / nanoparticle or microparticle complexes across brain endothelial cells and subsequent upregulation of LRP-1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Detailed Description Nanoparticles and Microparticles Nanoparticles and microparticles for use in the present invention can be any nanoparticle or microparticle suitable for delivery of a drug cargo to a target moiety in vivo. A "nanoparticle" as defined herein is any particle between 1 and 100 nm in size. A "microparticle" as defined herein is any particle greater than 0.1 μm and up to 100 μm in size. Nanoparticles or microparticles suitable for use in the present invention include polymersomes, liposomes, synthosomes, latex, micelles, nanocrystals, quantum dots, metal nanoparticles, oxide nanoparticles, silica nanoparticles, protein cages, nano- and microgels, dendrimers, virus-like particles, proteins, polymers, or other colloidal materials falling within the aforementioned size ranges. Typically, however, nanoparticles or microparticles for use in the present invention are polymersomes, liposomes, synthosomes, or micelles. Typically, the nanoparticles or microparticles are self-assembled structures.

[0017] The nanoparticles and microparticles of the invention may be of any feasible shape, for example substantially spherical, ellipsoidal, cylindrical, or bilayered, but typically are substantially spherical. Thus, substantially spherical nanoparticles for use in the invention have a (maximum) diameter of 1-100 nm, and substantially spherical microparticles for use in the invention have a (maximum) diameter of more than 0.1 μm up to 100 μm. Typically, the (maximum) diameter of the nanoparticles or microparticles of the invention is in the range of 50-5000 nm. More typically, said diameter is in the range of 50-1000 nm. Typically, the nanoparticles or microparticles for use in the invention have a number-average diameter of less than 300 nm, preferably less than 250 nm, and most preferably less than 200 nm or 150 nm. In one embodiment, the nanoparticles or microparticles for use in the invention are nanoparticles. Alternatively, the nanoparticles or microparticles for use in the invention are microparticles. Typically, the particle size is measured using a transmission electron microscope (TEM). Typically, the particle size distribution is measured using dynamic light scattering (DLS).

[0018] Preferably, the nanoparticle or microparticle for use in the present invention is a polymersome.Polymersome is a synthetic vesicle formed from amphiphilic block copolymers.Examples of polymersome are described in US 2010 / 0003336 A1, WO 2017 / 144849, WO 2017 / 158382, WO 2017 / 199023, WO 2017 / 191444, WO 2019 / 197834, WO 2020 / 144467 and WO 2020 / 225538, the contents of each of which are incorporated herein by reference in their entirety. Over the past 15 years, they have attracted significant research attention as versatile carriers due to their colloidal stability, tunable membrane properties, and ability to encapsulate or integrate other molecules (for one representative review article, see Lee and Feijen, J Control Release, 2012, 161(2), 473-83, the contents of which are incorporated herein by reference in their entirety).

[0019] Polymersomes are typically self-assembled structures. Polymersomes typically comprise amphiphilic block copolymers, i.e. block copolymers that comprise a hydrophilic block and a hydrophobic block. For example, polymersomes may comprise at least two such amphiphilic block copolymers that are different from each other.

[0020] Such copolymers can mimic biological phospholipids. The molecular weight of these polymers is much higher than that of naturally occurring phospholipid surfactants, and they can assemble into more entangled membranes (Battaglia and Ryan, J. Am. Chem. Soc., 2005, 127, 8757-8764, the contents of which are incorporated herein by reference in their entirety), providing final structures with improved mechanical properties and colloidal stability. Furthermore, the flexible nature of copolymer synthesis allows for the application of different compositions and functions over a wide range of molecular weights, and thus membrane thicknesses. Therefore, the use of these block copolymers as delivery vehicles is of great advantage.

[0021] Polymersomes are often substantially spherical. Polymersomes typically contain an amphiphilic membrane. The membrane is generally formed from two monolayers of amphiphilic molecules that align and intertwine to form a core surrounded by hydrophilic head groups that face the outside of the core and vesicle, and hydrophilic tail groups that form the inside of the membrane.

[0022] The thickness of the bilayer is generally between 2 and 100 nm, more typically between 2 and 50 nm (e.g., between 5 and 20 nm). These dimensions can be routinely measured, for example, using transmission electron microscopy (TEM) and / or small angle X-ray scattering (SAXS) (see, e.g., Battaglia and Ryan, J. Am. Chem. Soc., 2005, 127, 8757-8764, the contents of which are incorporated herein by reference in their entirety).

[0023] When a polymersome is formed from multiple different types of copolymers, different regions of the polymersome typically have different bilayer thicknesses. For example, when a polymersome is formed from two different copolymers, the thickness of the polymersome bilayer in the first region is preferably 1-10 nm, more preferably 2-5 nm. The thickness of the polymersome bilayer in the second region is preferably 5-50 nm, for example 10-40 nm. The thickness of the polymersome bilayer in the second region is more preferably 5-20 nm. Preferably, the thickness of the polymersome bilayer in the first region is less than the thickness of the polymersome bilayer in the second region. Alternatively, the copolymers can be of the same thickness but have different chemical compositions, which creates two different permeabilities, one copolymer forming a bilayer that is less permeable than the other.

[0024] In aqueous solutions, there is usually an equilibrium between different types of structures, for example polymersomes and micelles. It is preferred that at least 80 wt% of the structures in the solution are present as polymersomes, more preferably at least 90 wt% or 95 wt%, and most preferably all. This can be achieved using the methods outlined herein.

[0025] It is known that when two different polymersome-forming copolymers are mixed to form hybrid vesicles, they undergo phase separation, resulting in polymersomes that contain distinct regions corresponding to the distinct copolymers.For example, this phenomenon is described in detail in LoPresti et al., ACS NANO, 2011, 5(3), 1775-1784, the contents of which are incorporated herein by reference in their entirety.Polymersomes can be easily produced by applying these known synthetic principles.

[0026] Polymersomes can preferably dissociate and release encapsulated drugs when they reach the tissue of interest (i.e., target tissue). Non-limiting exemplary tissues of interest are described in detail below, including cells that cross the blood-brain barrier (e.g., CNS cells). Preferably, polymersomes can dissociate and release encapsulated drugs after being taken up into target cells (e.g., CNS cells) via endocytosis. Thus, polymersomes are preferably configured to bind to and cross the brain endothelial cells that constitute the blood-brain barrier.

[0027] Dissociation may be driven by a variety of mechanisms, such as pH sensitivity of the block copolymer, thermal sensitivity of the block copolymer, hydrolysis (ie, water sensitivity of the block copolymer), and / or redox sensitivity of the block copolymer.

[0028] The hydrophobic block of the copolymer contained in the polymersome may contain a cationizable pendant moiety as a pendant group. The cationizable moiety is, for example, a primary, secondary or tertiary amine, and an imidazole group, which can be protonated at a pH below a value in the range of 3 to 6.9. Alternatively, the group may be a phosphine.

[0029] The hydrophobic block of the polymersome preferably has a degree of polymerization of at least 50, more preferably at least 70. The degree of polymerization of the hydrophobic block is preferably not more than 250, even more preferably not more than 200. The degree of polymerization of the hydrophilic block is typically at least 10, preferably at least 15, more preferably at least 20. The ratio of the degree of polymerization of the (hydrophilic) to (hydrophobic) block is preferably in the range of 1:2.5 to 1:8. All these limitations promote the formation of polymersomes, rather than micelles.

[0030] The hydrophilic block may be based on condensation polymers such as polyesters, polyamides, polyanhydrides, polyurethanes, polyethers (including polyalkylene glycols, in particular polyethylene glycol (PEG)), polyimines, polypeptides, polypeptoids, polyureas, polyacetals and polysaccharides. Preferably, the hydrophilic block is based on a polymer selected from poly(alkylene glycol), poly(vinylpyrrolidone) (PVP), poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), poly(glycerol), poly(amino acids), polysarcosine, poly(2-oxazoline), poly[oligo(ethylene glycol)methyl methacrylate] and poly(N-(2-hydroxypropyl)methacrylamide). Most preferably, the hydrophilic block is based on PEG, poly(propylene glycol) or poly[oligo(ethylene glycol)methyl methacrylate]. The hydrophilic block may have zwitterionic pendant groups, in which case the zwitterionic pendant groups may be present in the monomer and remain unchanged during the polymerization process, or alternatively, the pendant functional groups of the monomer may be derivatized to become zwitterionic after polymerization.

[0031] In one embodiment of the present invention, the monomer forming the hydrophobic block is 2-(diisopropylamino)ethyl methacrylate (DPA) or 2-(diethylamino)ethyl methacrylate (DEA).

[0032] In another embodiment, the hydrophobic block is formed from 2-(diisopropylamino)ethyl methacrylate (DPA) or 2-(diethylamino)ethyl methacrylate (DEA) and the hydrophilic block is based on polyesters, polyamides, polyanhydrides, polyurethanes, polyethers, polyimines, polypeptides, polypeptoids, polyureas, polyacetals or polysaccharides. Preferably, the hydrophobic block is formed from 2-(diisopropylamino)ethyl methacrylate (DPA) or 2-(diethylamino)ethyl methacrylate (DEA) and the hydrophilic block is based on PEG, poly(propylene glycol) or poly[oligo(ethylene glycol)methyl methacrylate]. More preferably, the polymersomes for use in the present invention comprise a diblock PEG-PDPA, in which PEG is poly(ethylene glycol) and PDPA is poly(2-(diisopropylamino)ethyl methacrylate). Alternatively, polymersomes for use in the present invention comprise a diblock POEGMA-PDPA, in which POEGMA is poly[oligo(ethylene glycol)methyl methacrylate] and PDPA is poly(2-(diisopropylamino)ethyl methacrylate). A particularly preferred diblock copolymer is (P[(OEG) 10 MA 20 ]-PDPA 100 ). These copolymers have the ability to self-assemble in water or PBS to form vesicles with an aqueous lumen that can be loaded with drugs. The PEG functionality provides pendant hydroxyl groups that serve as handles for easy / reliable functionalization of the polymer with ligands (as discussed below) while avoiding protein opsonization (giving the polymersomes a long circulation time and low non-specific binding). On the other hand, PDPA is a pH-sensitive block that causes polymersome degradation at pH values ​​below 6.4, a typical pH during early-stage endocytosis. Due to the pH sensitivity, internalization of the polymersomes into the cell releases the drug payload into the cytosol.

[0033] The block copolymer may be a simple AB block copolymer, or an ABA or BAB block linear triblock copolymer, or (A) 2 B or A(B) 2 It may be a star copolymer, where A is a hydrophilic block and B is a hydrophobic block. It may be an ABC, ACB or BAC block linear triblock copolymer, or an ABC star copolymer (blocks linked together at the same end), where C is a different type of block. The C block may contain functional groups, such as crosslinkable or ionic groups, to allow for reaction of the copolymer, for example in new compositions. Crosslinking reactions, especially of ACB type copolymers, may provide useful stability to polymersomes. Crosslinking may be covalent in nature, or sometimes electrostatic. Crosslinking may involve the addition of a separate reagent to link functional groups, such as using a bifunctional alkylating agent to link two amino groups. Block copolymers may be star-shaped molecules with a hydrophilic or hydrophobic core, or comb-shaped polymers with a hydrophilic backbone (block) and hydrophobic pendant blocks, or vice versa. Such polymers may be formed, for example, by random copolymerization of monounsaturated macromers and monomers.

[0034] The microparticle or nanoparticle (e.g., polymersome) may also contain moieties provided on its surface that form an interference steric potential with the surface of the target cell, such as polymer brushes. Without wishing to be bound by a particular theory, in order to observe the highest level of selectivity of the binding of the polymersome to the desired target, each ligand on the surface of the nanoparticle or microparticle should individually have a very low binding affinity for its target receptor. In practice, selective ligands with such low binding energy for the target receptor are not readily available. To that end, in some embodiments of the present invention, the nanoparticle or microparticle includes polymer brushes on its outer surface to create a steric potential that moderates the strength of the binding of the ligand to the target receptor.

[0035] Typically, polymer brushes include naturally occurring polymers such as polypeptides or polysaccharides, or synthetic polymers such as any of the amphiphilic block copolymers mentioned above. Components on the outer surface of target cells, such as glycans, glycoproteins, and glycolipids (collectively referred to as the "glycocalyx"), are also believed to contribute to this repulsive steric potential. Preferred polymer components of polymer brushes include poly(ethylene glycol) (PEG), poly(vinylpyrrolidone) (PVP), poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), poly(glycerol), poly(sulfobetaine), poly(carboxybetaine), poly(amino acids), polysarcosine, poly(2-oxazoline), poly(N-(2-hydroxypropyl)methacrylamide), polyglycols, heparin, dextran, poly(ethylene glycol)-poly(2-(diisopropylamino)ethyl methacrylate) and / or poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA).

[0036] The polymer brush preferably has a degree of polymerization of at least 5, more preferably at least 10. The degree of polymerization of the polymer brush is preferably 500 or less, for example 300 or less, or 200 or less. The polymer brush preferably has a length of 1.5 to 350 nm, more preferably 3 to 210 nm.

[0037] The polymersomes of the present invention may include any of the structural and / or functional features of polymersomes described in any of WO 2017 / 144849, WO 2017 / 158382, WO 2017 / 199023, WO 2017 / 191444, WO 2019 / 197834, WO 2020 / 144467, and WO 2020 / 225538, the contents of each of which are incorporated herein by reference in their entirety.

[0038] Further details of suitable processes for polymerizing the monomers can be found in WO 03 / 074090, the contents of which are incorporated herein by reference in their entirety.

[0039] Exemplary methods that can be used to polymerize the monomers are atom transfer radical polymerization (ATRP) (see, for example, the exemplary methods described in Du et al., J. Am. Chem. Soc., 2005, 127, 17982-17983), living radical polymerization methods, functional NCA (N-carboxyanhydride) polymerization with efficient post-polymerization modification and ring-opening polymerization (ROP). Living radical polymerization has been found to provide polymers of monomers with polydispersity (in molecular weight) of less than 1.5 as determined by gel permeation chromatography. Polydispersity in the range of 1.2 to 1.4 for the or each block is preferred. Polymersomes can be loaded using pH change systems, electroporation or film hydration. In the pH change system process, the polymer is dispersed in an ionized form in an aqueous liquid and solubilized therein at relatively high concentrations without forming polymersomes. The pH is then changed such that some or all of the ionized groups are deprotonated to render them in their non-ionic form. At a second pH, the blocks become more hydrophobic and polymersomes form spontaneously.

[0040] A method of forming polymersomes having an encapsulated material (e.g., an encapsulated drug) in the core can include the following steps: (i) dispersing an amphiphilic copolymer in an aqueous medium; (ii) acidifying the composition formed in step (i); (iii) adding the material to be encapsulated to the acidified composition; and (iv) raising the pH to near neutral to encapsulate the material.

[0041] The method preferably includes a preliminary step of dispersing the amphiphilic copolymer in an organic solvent in a reaction vessel and then evaporating the solvent to form a film on the inside of the reaction vessel.

[0042] Step (ii), acidifying the composition, typically reduces the pH to a value below the pKa of the pendant group.

[0043] Another method of forming polymersomes with encapsulated material in their core may include the steps of: (i) dispersing the amphiphilic copolymer, and optionally the material to be encapsulated, in an organic solvent (e.g., a 2:1 chloroform:methanol mixture) in a reaction vessel; (ii) evaporating the solvent to form a film on the inside of the reaction vessel; and (iii) rehydrating the film with an aqueous solution that may contain the solubilized material to be encapsulated.

[0044] Another method of forming polymersomes with encapsulated material in their core may include the steps of: (i) dispersing an amphiphilic copolymer, and optionally an encapsulated material, in an organic solvent in a reaction vessel; (ii) adding an aqueous solvent to allow for solvent exchange and formation of polymersomes inside the reaction vessel; and (iii) optionally electroporating the resulting polymersomes to allow for encapsulation of water-soluble bioactive molecules.

[0045] UV spectroscopy and HPLC chromatography can be used to calculate encapsulation efficiency using techniques well known in the art. Alternative methods for forming polymersomes with encapsulated materials may include simple electroporation of materials and polymer vesicles in water. For example, drugs may be contacted in solid state with an aqueous dispersion of polymer vesicles and an electric field applied to form pores on the polymersome membrane. The solubilized material molecules can then enter the polymersome vesicles through the pores. This is followed by a self-repair process of the membrane, which allows the material molecules to be continuously incorporated inside the polymersome.

[0046] Alternatively, materials dissolved in organic solvents can be emulsified into an aqueous dispersion of polymer vesicles, thereby entrapping the solvent and materials in the core of the vesicles, followed by evaporation of the solvent from the system.

[0047] The polymersomes used in the present invention can be formed from two or more different block copolymers. In this embodiment, the method of forming the polymersomes uses a mixture of two or more block copolymers.

[0048] For example, 0.01% to 10% (w / w) of the material to be encapsulated is mixed with the copolymer in the manner described above.

[0049] Alternatively, the nanoparticle or microparticle for use in the present invention may be a liposome. Liposomes are spherical vesicles with at least one lipid bilayer. Typically, liposomes contain phospholipids, such as phosphatidylcholine, but may also contain other lipids, such as egg phosphatidylethanolamine, as long as they are compatible with lipid bilayer structure. The main types of liposomes include multilamellar vesicles (MLVs, with multiple lamellar phase lipid bilayers), small unilamellar liposomal vesicles (SUVs, with one lipid bilayer), large unilamellar vesicles (LUVs), and cochlear vesicles.

[0050] Typically, liposomes are fusogenic liposomes. This means that they can fuse with a membrane, for example, the cell surface membrane of a target cell, or the membrane of an endosome within the cell. When the bilayer of a fusogenic liposome fuses with the cell surface membrane, the liposome bilayer is incorporated into the cell surface membrane, and the drug cargo contained within the lysosome is released into the cell cytosol. Alternatively, liposomes may be incorporated into target cells via endocytosis, and the drug cargo incorporated within the liposome is released after the liposome bilayer fuses with the endosomal membrane. Since the pH within an endosome is weakly acidic, it is advantageous for the liposome to be pH sensitive, e.g., low pH reduces the stability of the liposome structure and promotes fusion with the endosomal membrane. Other environments with low pH (e.g., low pH found in tumors or inflammation sites) can also induce fusion of such liposomes.

[0051] The liposomes may be zwitterionic structures. Alternatively, the liposomes may be amphoteric liposomes, which means that the liposomes have an isoelectric point and are negatively charged at high pH values ​​and positively charged at low pH values. Exemplary pH-responsive elements in pH-sensitive liposomes include cholesterol hemisuccinate (CHEMS), palmitoyl homocysteine, dioleoyl glycerol hemisuccinate (DOG-Succ), etc.

[0052] Alternatively, nanoparticles or microparticles for use in the present invention may be synthosomes, a particular type of polymersome that has been engineered to contain channels (transmembrane proteins) that selectively allow certain chemicals to cross the membrane and enter or leave the vesicle.

[0053] Alternatively, the nanoparticles or microparticles for use in the present invention may be micelles. Micelles are aggregates (or supramolecular assemblies) of molecules that have both hydrophilic and hydrophobic regions and are dispersed in a liquid. Typically in aqueous solutions, the aggregated micelles are arranged such that the hydrophobic regions of the molecules are sequestered in the center of the micelle, while the hydrophilic regions of the molecules are present on the outer surface of the micelle and in contact with the aqueous medium. Typically, micelles are substantially spherical, although other shapes are possible, such as ellipsoids, cylinders, tori, and disks.

[0054] Alternatively, nanoparticles or microparticles for use in the present invention can be anything that is capable of encapsulating and / or conjugating any type of biologically active molecule, such as anti-cancer drugs, proteins, peptides (natural or non-natural), antibodies, antibody fragments, dyes, etc.

[0055] Targeting ligands for LRP-1 The nanoparticles or microparticles contain a ligand species on their outer surface that can bind to low density lipoprotein receptor-related protein 1 (LRP-1). A "ligand" is sometimes referred to herein as a "targeting moiety." By "on its outer surface" we mean that each ligand is positioned so that it can interact with its target (as opposed to being positioned in an inaccessible location that would prevent interaction with the target, e.g., by being encapsulated within the nanoparticle or microparticle).

[0056] As mentioned above, LRP-1 is a receptor that is highly expressed on brain endothelial cells that form the blood-brain barrier.Therefore, in a particularly preferred embodiment, the nanoparticles or microparticles for use in the present invention are configured to bind to the surface of brain endothelial cells.Typically, the ligand selectively binds to LRP-1, i.e., excludes significant levels of binding to other proteins.

[0057] In one embodiment, the ligand is a moiety that is attached to the outer surface of the nanoparticle or microparticle. Examples of suitable ligands include antibodies, antibody fragments, aptamers, oligonucleotides, small molecules, peptides, and carbohydrates. Peptide, protein, antibody, and antibody fragment ligands are particularly preferred. Peptides that bind to the receptor LRP-1 are known in the art. For example, Angiochem (Montreal, Canada) has developed peptides that exploit the LRP-1 mediated pathway to cross the blood-brain barrier when conjugated with a drug. One specific example of a peptide suitable for use in the present invention is Angiopep-2, a peptide with the sequence TFFYGGSRGKRNNFKTEEY. Further examples of suitable targeting moieties are disclosed in WO 2013 / 078562, the contents of which are incorporated herein by reference in their entirety (specifically, the ligand peptides disclosed therein are incorporated herein by reference). However, any such moiety can be used as a ligand in the present invention. The suitability of any given moiety to target LRP-1 can be determined using routine assays, including testing the ability of the moiety to specifically bind to the receptor.

[0058] It has been found that providing nanoparticles or microparticles featuring ligands that target the LRP-1 receptor can increase the clearance of amyloid-β from the basal (brain) side to the apical (blood) side of brain endothelial cells, resulting in a neuroprotective effect.

[0059] Without wishing to be bound by any particular theory, it is believed that the neuroprotective effect is the result of LRP-1 being transported from the apical to the basolateral side across brain endothelial cells, the mechanism of LRP-1 transport being via transcytosis. This process typically involves the following steps: (i) binding of an LRP-1 ligand to LRP-1 on the apical brain endothelial cell surface, (ii) internalization of LRP-1 (preferably as part of an LRP-1 / nanoparticle or LRP-1 / microparticle complex) into vesicular carriers within the brain endothelial cell by endocytosis, (iii) transport (or "trafficking") of LRP-1 (preferably an LRP-1 / nanoparticle or LRP-1 / microparticle complex) across the brain endothelial cell, and (iv) presentation of the transported LRP-1 (preferably an LRP-1 / nanoparticle or LRP-1 / microparticle complex) to the basolateral membrane of the brain endothelial cell via exocytosis (and in the case of an LRP-1 / nanoparticle or LRP-1 / microparticle complex, the nanoparticle or microparticle may subsequently dissociate from the complex). A similar mechanism of LRP-1 transport is believed to operate in any other endothelial cell in which LRP-1 is expressed.

[0060] In the transport step (iii) of this process, transport of LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle) is thought to be mediated by structures stabilized by syndapin-2; confocal laser scanning microscopy studies show that LRP-1 and syndapin-2 are colocalized during transport. The structures are typically tubular, or substantially tubular. It has been found that binding of the nanoparticles or microparticles described herein to the LRP-1 receptor on endothelial cells can facilitate this syndapin-2 mediated transcytosis mechanism, resulting in transport of the nanoparticles or microparticles and the LRP-1 receptor from one surface of the endothelial cell to the opposite surface (i.e., from the apical side to the basolateral side).

[0061] Thus, in some embodiments, the present invention provides a nanoparticle or microparticle as defined herein for use in a method of reducing amyloid-β and / or tau levels in an organ (e.g., the brain) of a patient in need thereof, wherein said method comprises binding of the nanoparticle or nanoparticle to an LRP-1 receptor on the surface of an endothelial cell (e.g., a brain endothelial cell) and subsequent transport of LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle complex) across said endothelial cell. Preferably, the nanoparticle or nanoparticle binds to an LRP-1 receptor on the apical surface of the endothelial cell. Preferably, transport of LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle complex) across the endothelial cell occurs via transcytosis. More preferably, transport of LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle complex) across the endothelial cell is mediated via a structure stabilized by syndapin-2. Preferably, after LRP-1 (or LRP-1 / nanoparticle or microparticle complex) has been transported across the endothelial cell, the LRP-1 (or LRP-1 / nanoparticle or microparticle complex) is presented on the basal surface of the endothelial cell. Preferably, in the case of transport of the LRP-1 / nanoparticle or microparticle complex, the microparticle or nanoparticle dissociates from the LRP-1 / nanoparticle or microparticle complex. Most preferably, the endothelial cell is a brain endothelial cell.

[0062] Thus, in some embodiments, the present invention provides a method for reducing amyloid-β and / or tau levels in an organ (e.g., the brain) of a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of nanoparticles or microparticles comprising a ligand species on their outer surface capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1), and the method further comprises binding of the nanoparticles or microparticles to LRP-1 on the surface of an endothelial cell (e.g., a brain endothelial cell) and subsequent transport of LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle complex) across the endothelial cell. Preferably, the nanoparticles or nanoparticles bind to the LRP-1 receptor on the apical surface of the endothelial cell. Preferably, transport of LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle complex) across the endothelial cell occurs via transcytosis. More preferably, transport of LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle complexes) across endothelial cells is mediated via structures stabilized by syndapin-2. Preferably, after LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle complexes) has been transported across endothelial cells, LRP-1 (or LRP-1 / nanoparticle or LRP-1 / microparticle complexes) are presented on the basal surface of endothelial cells. Preferably, in the case of transport of LRP-1 / nanoparticle or LRP-1 / microparticle complexes, the microparticle or nanoparticle dissociates from the LRP-1 / nanoparticle or LRP-1 / microparticle complex. Most preferably, the endothelial cells are brain endothelial cells.

[0063] Moreover, it was found that the promotion of transcytosis mechanisms is associated with increased LRP-1 expression in endothelial cells, which may allow LRP-1 to accumulate at the basal side of endothelial cells, favoring the clearance of both amyloid-β and tau proteins from organs, such as the brain.

[0064] Thus, in some embodiments, the present invention provides a nanoparticle or microparticle as defined herein for use in a method of reducing levels of amyloid-β and / or tau in an organ (e.g., the brain) of a patient in need thereof, wherein the method comprises binding of the nanoparticle or microparticle to an LRP-1 receptor on the surface of an endothelial cell (e.g., a brain endothelial cell), and further comprises increasing LRP-1 expression in the endothelial cell.

[0065] Thus, in some embodiments, the present invention provides a method of reducing amyloid-β and / or tau levels in the brain of a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of nanoparticles or microparticles comprising a ligand species on their outer surface capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1), and wherein the method further comprises binding of the nanoparticles or microparticles to LRP-1 on the surface of endothelial cells (e.g., brain endothelial cells), and further comprises increasing LRP-1 expression in endothelial cells.

[0066] Furthermore, it is believed that the structural features of the nanoparticles or microparticles may affect the degree to which the LRP-1 transcytosis mechanism is promoted. In particular, the inventors have found that the correlation between the avidity of the nanoparticles or microparticles and the promotion of transcytosis is nonlinear. As used herein, the term "avidity" refers to the accumulated strength of the affinities of multiple individual ligand-receptor interactions. Thus, a polymersome that contains many ligands on its outer surface that bind to LRP-1 will typically have a higher avidity than a polymersome of the same size that contains fewer such ligands on its outer surface, since a higher total number of ligand-receptor interactions are possible. A polymersome that contains stronger LRP-1 binding ligands on its outer surface is expected to have a higher avidity than a corresponding polymersome that contains less strong LRP-1 binding ligands on its outer surface. As the avidity increases from a low level to a high level, the transcytosis of LRP-1 is promoted. However, as the avidity continues to increase to higher levels, the amount of transcytosis of LRP-1 observed decreases again. High avidity nanoparticles or microparticles are believed to promote degradation of LRP-1 instead of transcytosis.

[0067] Thus, there exists a "sweet spot" for the binding activity of nanoparticles or microparticles for use in the present invention to maximize transcytosis of LRP-1 from the apical to the basolateral side of endothelial cells.

[0068] Therefore, the avidity of the nanoparticle / microparticle-LRP-1 interaction is a relevant parameter for the design of optimal nanoparticles / microparticles to achieve the maximum level of the desired pharmacological effect. The inventors have developed an empirical formula for determining the optimal nanoparticle / microparticle avidity. Specifically, the number of ligand species (λA) on the outer surface of the microparticle or nanoparticle is preferably such that the properties of the microparticle or nanoparticle satisfy the following relationship:

[0069]

number

[0070] (In the formula: λ is the density of ligand species on the outer surface of a microparticle or nanoparticle (nm 2 (number per unit); A is the surface area of ​​the microparticle or nanoparticle (nm 2 ) and; ζ is the number of LRP-1 receptors accessible to the nanoparticle, thus ζ=ΓΑ (where Γ is the surface density of LRP-1 (nm 2 (number per unit area), and A is as defined above); β = (k B T) -1 (In the formula, k B is the Boltzmann constant (JK -1 ) and T is the absolute temperature (Kelvin); ε B is the single energy (J) of binding of the ligand species / LRP-1 receptor pair; and u S is the steric potential (J) between the nanoparticle or microparticle and the cell surface.)

[0071] For the avoidance of doubt, in the above relationship the symbol ε means that the value of the expression lies between the two integers in the square brackets, namely 20 and 40.

[0072] The relevant parameters in the formula can be readily determined by one skilled in the art, for example using the methods described below.

[0073] The number (and density) of each type of ligand on the outer surface of a polymersome can typically be controlled during synthesis of the polymersome by varying the ratio of ligand-conjugated copolymer to "pristine" copolymer (i.e., diblock copolymer with no attached ligand). For any given system, the number of ligands per polymersome is given by the self-assembly parameters of the copolymer (related to the polymer molecular weight and packing ratio) and the size of the polymersome. The number of each type of ligand (and therefore the density of receptors) on the outer surface of a polymersome can typically be confirmed using mass spectrometry.

[0074] The surface area of ​​nanoparticles or microparticles can be measured by several microscopic techniques, such as transmission electron microscopy, scanning electron microscopy, atomic force microscopy, and the like, as well as by scattering techniques, such as dynamic or static light scattering. Preferably, the surface area is measured by transmission electron microscopy.

[0075] Single-ligand binding potential ε between a given ligand and the LRP-1 receptor B can be experimentally measured by binding assays such as surface plasmon resonance spectroscopy, isothermal titration calorimetry, radiolabeling, or fluorescent labeling. It can also be computationally estimated using molecular docking or molecular dynamics methods.

[0076] Stereo potential u s u S =u P +u G The steric potential arising from the glycocalyx brush on the cell surface (u P ), and the steric potential arising from the polymer brushes covering the nanoparticles (u G ) is the sum of u P and u G The magnitude of depends on the accessibility of the ligand and the receptor. These values ​​can be derived as follows:

[0077]

number

[0078] (In the formula: β is as defined above; R is the radius of the nanoparticle (nm), which can typically be determined using the same microscopy techniques as for the surface area determination above; δ G is the average glycocalyx thickness

[0079]

number

[0080] (In the formula, d PG is the average length of a proteoglycan, which is typically about 4.5 nm, as estimated from available structures in protein databases, and b GAG is the Khun length of the GAG ​​chain, typically 7 nm, and N GAG is the degree of polymerization of the GAG ​​chain, typically between 80 and 100) and the length of extracellular LRP-1, which can be readily obtained from structural biology databases known in the art and is typically 60 nm; δ P is the length of the polymer that stabilizes the nanoparticle surface, h P is the ratio between the ligand-polymer tether and the ligand-polymer tether; both values ​​are fixed by the nanoparticle design;

[0081]

number

[0082] and the volume of the LRP-1 segment that engages the ligand, which varies with the type of ligand, r L is the distance between the ligand binding site and the tip of LRP-1, which can be readily determined by one of skill in the art using molecular modeling techniques, and for Angiopep-2 this is estimated from molecular modeling to be approximately 3.5 nm; σ GAG is the surface area occupied by one GAG ​​chain on the cell surface; and σ P is the surface area occupied by one polymer chain on the nanoparticle, and it is predefined during the design of the nanoparticle.)

[0083] Surface density of LRP-1 (nm 2 (number of GAG chains per unit area) Γ, and the surface area occupied by one GAG ​​chain σ GAG Both can be determined by in vitro binding assays to endothelial cells (e.g., brain endothelial cells) using well-defined, homogeneous nanoparticles decorated with a variable number of ligands. An example of a procedure for measuring LRP-1 expression levels is provided in Example 1 below.

[0084] This formula therefore provides a useful and novel empirical tool for determining the optimal number of LRP-1 ligands on the exterior surface of nanoparticles or microparticles for use in the present invention.

[0085] A plot showing the effect of LRP-1 receptor density, polymersome radius, and ligand number (i.e., the key parameters in the above formula that can be influenced by polymersome design and the system being targeted) on the binding energy of total LRP-1 / nanoparticles or microparticles in brain endothelial cells is shown in Figure 9. The black / darkest areas of the graph indicate stronger than optimal affinity of polymersomes to the target cells, resulting in endocytosis of LRP-1 receptors primarily in brain endothelial cells. The grey areas of the graph indicate weaker than optimal binding of polymer to the target cells. The white / lightest areas of the graph indicate optimal levels of binding of polymersomes to LRP-1 on the brain endothelial cell surface, which promotes transcytosis of LRP-1 / polymersome complexes across brain endothelial cells, and subsequent upregulation of LRP-1. This is the region that corresponds to systems where the value of the above formula is between 20 and 40. Thus, it is clear that there exists a “sweet spot” in total LRP-1 / nanoparticle or microparticle binding energy that is achievable by smart nanoparticle or microparticle design, leading to the most efficient operation of the LRP-1 transcytosis mechanism, as well as an upregulation that ultimately promotes the clearance of amyloid beta and tau from the brain.

[0086] The nanoparticles or microparticles typically comprise between 2 and 1000 ligands of a ligand species that bind to LRP-1, preferably between 5 and 500 ligands of a ligand species, more preferably between 10 and 200 ligands of a ligand species, even more preferably between 15 and 100 ligands of a ligand species, and most preferably between 20 and 50 ligands of a ligand species.

[0087] The LRP-1 ligand is typically attached to a polymer component on the outer surface of the nanoparticle or microparticle. In the case of polymersomes, the ligand is typically attached to a hydrophilic block of an amphiphilic diblock copolymer.

[0088] Routine techniques can be used to attach the ligand to the outer surface of the nanoparticle or microparticle, for example by adapting known methods for attaching the ligand to polymers, drugs, nucleic acids, antibodies, and other substances. Attachment can be non-covalent (e.g., electrostatic) or covalent, but is preferably covalent. For example, when the nanoparticle or microparticle is a polymersome, the targeting moiety can be attached by reacting a suitable functional group (including, but not limited to, amine, carboxyl, and thiol groups) on the targeting moiety with a corresponding functional group on at least one copolymer that forms or will form a polymersome. This attachment can be achieved either before the copolymer forms a polymersome structure or after the polymersome is formed.

[0089] In a particularly preferred embodiment, the nanoparticle or microparticle is a polymersome that comprises a polymer brush on its outer surface that includes poly(ethylene glycol)-poly(2-(diisopropylamino)ethyl methacrylate) and a respective ligand species. The ligand is then inserted into the polymer brush of the polymersome formed from poly(ethylene glycol)-poly(2-(diisopropylamino)ethyl methacrylate), typically using a solvent exchange method. Typically, the density of the ligand within the brush can also be varied.

[0090] Ligands can also be attached to copolymers by first chemically activating either or both of the ligand and the copolymer. For example, peptide ligands can be activated by adding reactive species to one of their termini, such as cysteine ​​moieties (whose thiol groups are well known to react easily with functional groups, such as the widely used maleimide moieties). Similarly, copolymers can be activated by functionalizing them with reactive species (e.g., maleimide moieties, if the targeting moiety has a thiol group). Copolymers can be provided with such reactive species by functionalizing the copolymer itself, or by providing suitable monomers before polymerization to form the copolymer, or by providing suitable initiators for polymerization.

[0091] In a particularly preferred embodiment, the nanoparticles or microparticles are polymersomes in which one or more ligands on the outer surface of the polymersome are covalently attached to poly(ethylene glycol) molecules. In this way, by attaching the ligands to PEG molecules of different chain lengths, the depth of ligand insertion into the polymer brushes can be controlled. This is due to the steric repulsion potential u between the ligand and the receptor on the surface of the target cell. s As discussed above, this steric potential is an important factor in determining the optimal number of ligands on the surface of a nanoparticle or microparticle for binding to a particular cell type.

[0092] The ligands can be attached directly onto the exterior surface of the nanoparticle or microparticle, or alternatively, can be attached via a chemical spacer.

[0093] When the nanoparticle or microparticle is a polymersome, the ligand may be a pendant group of the polymer contained in the polymersome (i.e., at least one of the copolymers that form the polymersome itself). Obviously, in this embodiment, it is not necessary to carry out a separate synthetic step to attach the ligand to the copolymer or to the resulting polymersome.

[0094] Suitable pendant groups generally include any group that corresponds to a ligand defined elsewhere herein. In one exemplary embodiment, the targeting moiety is a phosphorylcholine moiety, i.e., a group having the formula:

[0095] [ka]

[0096] It is a group having the formula: The phosphorylcholine moiety is a zwitterionic moiety that can constitute a pendant group in one or more of the monomers that form the copolymer contained in the polymersome.

[0097] The phosphorylcholine moiety selectively targets scavenger receptor class B, member 1 (SCARB1), which is overexpressed by macrophages and other immune cells; allowing polymersomes specifically featuring phosphorylcholine moieties to enter such cells.

[0098] In some embodiments, nanoparticles or microparticles for use in the present invention may comprise multiple species of ligands on their outer surface that target LRP-1, and thus the nanoparticles or microparticles may comprise combinations of two, three, four, five or more such ligands.

[0099] The binding of nanoparticles or microparticles to LRP-1 also allows the nanoparticles or microparticles themselves to cross the BBB. Any drug encapsulated within the nanoparticles or microparticles can then be effectively delivered to both the CNS parenchyma and CNS cells. In particular, it was found that the endothelial transcytosis mechanism does not involve acidification of the nanoparticles or microparticles in the membrane-transport organelles, which is important to avoid premature collapse of the polymersomes and the associated release of the encapsulated drug. Furthermore, the LRP-1 receptor is associated with traditional endocytosis in CNS cells, aiding in the delivery of the drug into the cytosol (via the collapse of the nanoparticles or microparticles) after transport across the BBB.

[0100] Further targeting ligands In some embodiments, a nanoparticle or microparticle for use in the present invention may comprise, on its outer surface, in addition to the ligand species that binds to LRP-1, at least one further ligand species that binds to a different complementary receptor. Thus, the nanoparticle or microparticle may comprise a second ligand species capable of binding to a second receptor species on the surface of an endothelial cell (e.g., a brain endothelial cell). The nanoparticle or microparticle may also comprise a third, fourth, fifth, or more ligand species capable of binding to a third, fourth, fifth, or more receptor species on the surface of an endothelial cell (e.g., a brain endothelial cell). In one embodiment, the nanoparticle or microparticle comprises, on its outer surface, 2 to 7 different ligand species, each of which is capable of binding to a complementary receptor species on the cell surface. Preferably, in this embodiment, the nanoparticle or microparticle of the present invention comprises, on its outer surface, 2 to 6 different ligand species, more preferably 3 to 5 different ligand species, and most preferably 4 different ligand species. Thus, the nanoparticle or microparticle comprises, on its outer surface, in addition to the ligand that targets LRP-1, 1 to 5 further ligand species. Preferably, the nanoparticles or microparticles comprise from 2 to 4 additional ligand species, most preferably 3 additional ligand species.

[0101] Typically, in this embodiment, the nanoparticles or microparticles comprise 2 to 1000 ligands of the second ligand type. Preferably, the nanoparticles or microparticles comprise 5 to 1000 ligands of the second ligand type, more preferably 10 to 500 ligands of the second ligand type, even more preferably 20 to 200 ligands of the second ligand type, and most preferably 50 to 100 ligands of the second ligand type.

[0102] Typically, in this embodiment, the nanoparticles or microparticles comprise 2 to 1000 ligands of the subsequent (i.e., tertiary or higher) ligand species. The nanoparticles or microparticles preferably comprise 5 to 1000 ligands of the subsequent ligand species, more preferably 10 to 500 ligands of the subsequent ligand species, even more preferably 20 to 200 ligands of the subsequent ligand species, and most preferably 50 to 100 ligands of the subsequent ligand species.

[0103] Typically, the combination of ligands on the surface of the nanoparticles or microparticles is 8k B T~30k B T (where k B is the Boltzmann constant and T is temperature). Without wishing to be bound by theory, this is believed to lead to an on-off binding profile for the nanoparticles or microparticles, in which the receptors are saturated only above a given onset receptor density, while the nanoparticles or microparticles do not bind at all at lower receptor densities.

[0104] Each ligand type is adapted to allow the nanoparticle or microparticle to bind to a target. Typically, the ligand selectively binds to the target. The target is a chemical entity present on or near the tissue of interest (thus allowing the nanoparticle or microparticle to accumulate specifically in the tissue of interest, preferentially over other sites). The target is preferably a receptor, e.g., a receptor that is particularly abundant in the target tissue of interest. Most preferably, the target is a receptor on or in a cell surface membrane.

[0105] Each ligand species can be any ligand that specifically binds to a target. As is well known in the art, a wide range of substances can be used as ligands, e.g., to target receptors, e.g., from the well-developed field of bioconjugates.

[0106] In one embodiment, each ligand is a moiety attached on the outer surface of the nanoparticle or microparticle. Examples of suitable ligands include antibodies, antibody fragments, aptamers, oligonucleotides, small molecules, peptides and carbohydrates. Peptide, protein, antibody and antibody fragment ligands are particularly preferred. However, any such moiety can be used as a ligand in the present invention. The suitability of any given moiety to target any given receptor can be determined using routine assay methods, including testing the ability of the moiety to specifically bind to the receptor.

[0107] Without wishing to be bound by any particular theory, it is believed that multiplexing ligands on the surface of nanoparticles or microparticles in this manner confers the property of "superselectivity" for target cells. This concept is discussed in detail in WO 2020 / 225538, the contents of which are incorporated herein by reference in their entirety. In essence, the principle behind "superselectivity" is that when multiple different ligand species are present on the nanoparticle or microparticle scaffold surface, the nanoparticles / microparticles become highly selective for their target cell populations, leaving other cells untouched.

[0108] Thus, polymersomes functionalized with two or more ligand species are likely to bind effectively to target cells, although each may have a relatively low affinity for the target receptor and avoid targeting undesirable cells. Furthermore, mutations in cell surface receptors are unlikely to lead to evasion of detection by nano- or microparticles.

[0109] Examples of other receptors that are highly expressed on endothelial cells that form the blood-brain barrier (in addition to LRP-1) and that can be targeted by secondary (or higher order) ligands on the outer surface of nanoparticles or microparticles include scavenger receptor class B, member 1 (SCARB1), transferrin receptor (TFRC), folate receptor 1 (FOLR1), and epidermal growth factor receptor (EGFR).

[0110] In one embodiment, the nanoparticles or microparticles contain an additional ligand species, preferably one ligand species, that targets the SCARB1 receptor. The protein encoded by this gene is a cell membrane receptor for high density lipoprotein cholesterol (HDL), which promotes the uptake of cholesterol esters from circulating lipoproteins. Further findings suggest that SCARB1 plays an important role in cholesterol metabolism, signal transduction, motility, and proliferation of cancer cells, and thus may have a significant impact on carcinogenesis and metastasis. Malignant tumors show significant heterogeneity, to the extent that different types of cells with different genetic backgrounds can be found even in the same tissue site. In contrast, SCARB1 has been found to be consistently overexpressed in most tumor cells (e.g., HeLa and FaDu cells). Recent findings show that the level of SCARB1 expression correlates with aggressiveness and poor survival in certain cancers. SCARB1 is also a receptor for the Hepatitis C virus glycoprotein E2.

[0111] Ligands that bind to SCARB1 are known in the art. One such ligand is poly(2-(methacryloyloxy)ethylphosphorylcholine) (PMPC).

[0112] Thus, in one embodiment, one ligand species on the nanoparticle or microparticle scaffold targets LRP-1 and another ligand species on the scaffold targets SCARB1.

[0113] In another embodiment, the nanoparticle or microparticle contains an additional ligand species, preferably one ligand species, that targets TFRC. This gene encodes a cell surface receptor that is required for cellular iron uptake by the process of receptor-mediated endocytosis. This receptor is required for erythropoiesis and neurogenesis.

[0114] As an important element, iron plays a vital role in various physiological and pathological processes. Iron metabolism operates at two levels: systemic and cellular, which are normally in a balanced state. Disturbances in iron metabolic balance are associated with many types of diseases, such as Alzheimer's disease, osteoporosis, and various cancers. In systemic iron metabolism, which is controlled by the hepcidin-ferroportin axis, plasma iron binds to transferrin (TF), which has two high-affinity binding sites for ferric iron. General cellular iron metabolism consists of iron uptake, utilization, and excretion. In the iron uptake process in general cells, the transferrin receptor (TFR) serves as the most important receptor-mediated control. TFR1 and TFR2 are two subtypes of TFR that bind to the iron-transferrin complex and promote the uptake of iron into cells. TFR1 is ubiquitously expressed on the general cell surface, while TFR2 is specifically expressed in hepatocytes. TFR1 has received more attention than TFR2 due to its diverse functions in both invertebrates and vertebrates. Recent reports have shown that TFR1 is involved in many kinds of diseases, such as anemia, neurodegenerative diseases, and cancer. Most importantly, TFR1 has been confirmed to be abnormally expressed in various cancers. Therefore, TFR1 has been hypothesized as a possible molecular target for the diagnosis and treatment of cancer therapy.

[0115] Thus, in one embodiment, one ligand species on the nanoparticle or microparticle scaffold targets LRP-1 and another ligand species on the scaffold targets TFRC.

[0116] In another embodiment, the nanoparticle or microparticle contains an additional ligand species, preferably one ligand species, that targets FOLR1.The protein encoded by this gene is a member of the folate receptor family.The members of this gene family bind folic acid and its reduced derivatives and transport 5-methyltetrahydrofolate into cells.The gene product is a secreted protein that is either membrane-anchored via glycosyl-phosphatidylinositol linkage or exists in soluble form.Mutations in this gene are associated with neurodegeneration due to impaired brain folate transport.

[0117] The folate cycle maintains important metabolic reactions and is essential for rapidly growing cells. Under physiological conditions, exogenous reduced folate (a water-soluble vitamin B) is mainly transported into cells via the low-affinity, high-capacity, ubiquitously expressed reduced folate carrier (RFC; bidirectional anion exchange mechanism). Once inside the cell, folate plays an essential role in the biosynthesis of purines and thymidine, which are then required for DNA synthesis, methylation, and repair. Folate is also transported by the high-affinity FR. In humans, there are four isoforms of FR (FRα, FRβ, FRγ, FRδ). FRα, FRβ, and FRδ are attached on the cell surface by glycosylphosphatidylinositol anchors, while FRγ is a secreted protein. Since FRα is expressed on the cell surface in a tumor-specific manner, it offers the possibility of tumor localization as well as selectively delivering therapeutic agents to malignant tissues and minimizing concomitant toxic side effects.

[0118] There are many unique advantages to utilizing FRs as diagnostic and therapeutic targets. First, FRα is located on the luminal surface of epithelial cells in most proliferating non-tumor tissues and is inaccessible to the circulation. In contrast, FRα is expressed throughout the cells of malignant tissues and is accessible via the circulation. Second, FRs have the ability to bind folate, a relatively harmless small molecule that can rapidly penetrate solid tumors and is amenable to chemical conjugation with other molecules. Once the folate conjugate binds to the FR, it is internalized within the cell and FRα is rapidly recycled back to the cell surface via the FR-mediated endocytic pathway. All these factors highlight the possible role of FRα in the diagnosis and treatment of specific tumor types.

[0119] Thus, in one embodiment, one ligand species on the nanoparticle or microparticle scaffold targets LRP-1 and another ligand species on the scaffold targets FOLR1.

[0120] In another embodiment, the nanoparticle or microparticle contains an additional ligand species, preferably one ligand species, that targets EGFR.The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily.This protein is a receptor for a member of the epidermal growth factor family.EGFR is a cell surface protein that binds to epidermal growth factor.When this protein binds to the ligand, it induces receptor dimerization and tyrosine autophosphorylation, leading to cell proliferation.

[0121] The epidermal growth factor receptor (EGFR) is a large family of receptor tyrosine kinases (TKs) expressed in several types of cancer, including breast, lung, esophageal, and head and neck. EGFR and its family members are major contributors to a complex signaling cascade that regulates cancer cell proliferation, signaling, differentiation, adhesion, migration, and survival. EGFR binds to its cognate ligand EGF, further inducing tyrosine phosphorylation and receptor dimerization with other family members, resulting in enhanced and uncontrolled proliferation. Due to its multifaceted role in cancer progression, EGFR and its family members have emerged as attractive candidates for anticancer therapy. Specifically, aberrant activity of EGFR has been shown to play a key role in tumor cell development and proliferation, in which it is involved in many cellular responses, such as proliferation and apoptosis. The epidermal growth factor receptor (EGFR) signaling pathway is also a strong candidate to initiate and determine clinical outcomes in many respiratory diseases. Deregulation of the EGFR pathway leading to aberrant EGFR signaling is associated with early stage pathogenesis of pulmonary fibrosis, cancer, and many airway hypersecretory diseases such as COPD, asthma, and cystic fibrosis.

[0122] Thus, in one embodiment, one ligand species on the nanoparticle or microparticle scaffold targets LRP-1 and another ligand species on the scaffold targets EGFR.

[0123] Ligands that bind to each of these receptors are well known in the art. Examples of ligands for LRP-1 and SCARB1 are described above. Examples of ligands for TFRC, such as TFR1, are transferrin and transferrin mimic peptides. Examples of ligands for FOLR1 are folic acid. Examples of ligands for EGFR are peptide YHWYGYTPQNVI peptide.

[0124] Encapsulated drugs Nanoparticles or microparticles for use in the present invention may optionally include a drug encapsulated within the nanoparticle or microparticle. For the avoidance of doubt, it is also possible to encapsulate multiple different drugs within a single nanoparticle or microparticle, or to provide multiple nanoparticles or microparticles each containing a particular encapsulated drug.

[0125] As will be readily appreciated, the encapsulated drug will be selected according to the disorder being treated, non-limiting examples of which are described elsewhere in this disclosure.

[0126] Typically, the encapsulated drug is selected from anti-Alzheimer's drugs, drugs for treating cerebrovascular disease, and / or drugs useful for reducing amyloid-β and / or tau levels or inhibiting the formation of amyloid-β and / or tau. Thus, in some embodiments, the encapsulated drug is an anti-Alzheimer's drug. In other embodiments, the encapsulated drug is a drug for treating cerebrovascular disease. In other embodiments, the encapsulated drug is a drug useful for reducing amyloid-β and / or tau levels. In other embodiments, the encapsulated drug is a drug useful for inhibiting the formation of amyloid-β and / or tau.

[0127] Non-limiting examples of such drugs include donepezil, galantamine, rivastigmine, memantine, and combinations thereof.

[0128] Pharmaceutical Compositions The nanoparticles or microparticles of the invention can be formulated into pharmaceutical compositions using routine techniques known in the art, such as those already utilized to formulate nanoparticles or microparticles, such as polymersomes or drug-containing liposomes.

[0129] The pharmaceutical composition comprises a plurality of nanoparticles or microparticles of the present invention. It also contains one or more pharma- ceutically acceptable excipients. The one or more pharma-ceutically acceptable excipients can be any suitable excipient. The pharmaceutical composition is typically aqueous, i.e., it comprises water (especially sterile water). Common pharmaceutical excipients include lubricants, thickeners, wetting agents, emulsifiers, suspending agents, preservatives, fillers, diluents, binders, preservatives and adsorption enhancers, such as surface penetrating agents. Solubilizers and / or stabilizers, such as cyclodextrins (CD), can also be used. Those skilled in the art will be able to select the appropriate excipients according to the purpose. Common excipients that may be used in the pharmaceutical products described herein are listed in various handbooks (e.g., Pharmaceutical excipients, DE Bugay and WP Findlay (eds.), Marcel Dekker, New York, 1999; Fiedler Encyclopedia of Excipients for Pharmaceuticals, Cosmetics and Related Areas, EM Hoepfner, A. Reng and PC Schmidt (eds.), Munich, 2002; and Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete, ed., HP Fielder (ed.), Aulendorf, 1989, the contents of all of which are incorporated herein by reference in their entirety).

[0130] The typical pH of the aqueous pharmaceutical composition is 7.0 to 7.6, preferably 7.2 to 7.4. A pharma-ceutically acceptable buffer may be used to achieve the required pH. The pharmaceutical composition may be in the form of a sterile isotonic saline solution.

[0131] The pharmaceutical compositions of the present invention can be administered to a patient by any one or more of the following routes: orally, systemically (e.g., transdermally, nasally, transmucosally, or via suppository), or parenterally (e.g., intramuscularly, intravenously, or subcutaneously). The compositions of the present invention can take the form of a tablet, pill, capsule, semisolid, powder, sustained release formulation, solution, suspension, elixir, aerosol, transdermal patch, bioadhesive film, or any other suitable composition. Typically, however, the pharmaceutical composition is an injectable composition, e.g., suitable for parental administration, and preferably suitable for intravenous administration, e.g., by infusion.

[0132] Medical Uses of Nanoparticles or Microparticles The nanoparticles or microparticles of the present invention can cross the blood-brain barrier and target tissues, including but not limited to cells (e.g., CNS cells), and can promote basal to apical removal of amyloid-β and tau protein from the brain.As mentioned above, high efficiency in targeting is at least partially due to the presence of an appropriate number of ligands (i.e., targeting moieties) on the outer surface of the nanoparticle or microparticle (e.g., as part of the polymer itself or as a separate moiety attached thereto) that target the receptor LRP-1.

[0133] Thus, the present invention provides nanoparticles or microparticles as defined herein for use in a method of reducing amyloid-β and / or tau levels in a patient in need thereof. Thus, in one embodiment, the nanoparticles or microparticles are for use in a method of reducing amyloid-β and / or tau levels in a patient. The patient is typically a mammal, more typically a human patient. Amyloid-β and / or tau may be removed from any organ or tissue in which it has accumulated to high levels. Preferably, the organ from which amyloid-β and / or tau may be removed is the brain. Examples of other organs from which amyloid-β and / or tau may be removed include the heart and kidneys.

[0134] Particular diseases that can be treated by the nanoparticles or microparticles described herein include Alzheimer's disease and cerebrovascular disorders.

[0135] Thus, in some embodiments, the present invention provides nanoparticles or microparticles as defined herein for use in a method of treating or preventing Alzheimer's disease in a patient.

[0136] In another embodiment, the present invention provides a nanoparticle or microparticle as defined herein for use in a method of treating or preventing a cerebrovascular disorder in a patient.

[0137] The present invention also provides a method of reducing amyloid-β and / or tau levels or inhibiting amyloid-β in the brain, wherein the method comprises administering to the patient a therapeutically effective amount of the nanoparticles or microparticles described herein.

[0138] In some embodiments, the present invention provides a method of treating or preventing Alzheimer's disease in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of the nanoparticles or microparticles described herein.

[0139] In another embodiment, the present invention provides a method of treating or preventing a cerebrovascular disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of the nanoparticles or microparticles described herein.

[0140] The present invention also provides the use of the nanoparticles or microparticles described herein for the manufacture of a medicament for reducing amyloid-β and / or tau levels in the brain of a patient in need thereof.

[0141] In some embodiments, the present invention provides the use of the nanoparticles or microparticles described herein for the manufacture of a medicament for treating or preventing Alzheimer's disease in a patient in need thereof.

[0142] In another embodiment, the present invention provides the use of a nanoparticle or microparticle as described herein for the manufacture of a medicament for treating or preventing a cerebrovascular disorder in a patient in need thereof.

[0143] In some embodiments, the nanoparticles and microparticles of the present invention, comprising an encapsulated drug selected from anti-Alzheimer's drugs and / or drugs useful for reducing amyloid-β and / or tau levels or inhibiting the formation of amyloid-β and / or tau, are for use in a method for reducing amyloid-β and / or tau levels or inhibiting the formation of amyloid-β and / or tau in a patient in need thereof. The activity of such nanoparticles and microparticles typically results from both (i) the effect of polymersomes on the trafficking and expression of LRP-1 in brain endothelial cells, and (ii) the encapsulated drug being released at the target site in the brain. As will be readily understood, the encapsulated drug is selected depending on the disease to be treated. Preferably, the encapsulated drug is selected from donepezil, galantamine, rivastigmine and memantine.

[0144] Naturally, medical applications and treatments include administration of a therapeutically effective amount of nanoparticles or microparticles. A therapeutically effective amount of nanoparticles or microparticles is administered to a patient. As used herein, the term "therapeutically effective amount" refers to an amount of a biologically active molecule sufficient to reduce or ameliorate the severity, duration, progression or onset of the disorder being treated, prevent the progression of the disorder being treated, cause regression, prevent recurrence, onset or progression of symptoms associated with the disorder being treated, or enhance or improve the prophylactic or therapeutic effects of another therapy. The exact amount of biologically active molecule administered to a patient will depend on the type and severity of the disease or condition, as well as the characteristics of the patient, such as general health, age, sex, weight, and tolerance to the drug. It will also depend on the extent, severity, and type of disorder being treated. Those skilled in the art will be able to determine appropriate dosages depending on these and other factors. However, typical dosages are between 0.001 and 1000 mg, measured as weight of the drug, depending on the activity of the particular drug, the age, weight, and condition of the subject being treated, the type and severity of the disease, and the frequency and route of administration. Preferably, daily dosage levels are between 0.001 mg and 4000 mg.

[0145] The nanoparticles, microparticles, or pharmaceutical compositions containing such nanoparticles or microparticles can be administered to a patient by any suitable method. However, preferably, the nanoparticles or microparticles are administered parenterally (e.g., by intramuscular, intravenous, or subcutaneous injection). Most preferably, the nanoparticles or microparticles are administered by injection. EXAMPLES

[0146] Example 1: Effect of polymersomes with LRP-1 targeting ligands on LRP-1 expression and amyloid-β clearance from the brain Each polymersome (AP) was functionalized with 22 Angiopep-2 ligands on the outer surface. 22 -POs) were synthesized.

[0147] Synthetic vesicles were prepared using amphiphilic copolymers made with poly(ethylene glycol) (PEG) as the hydrophobic block and poly(2-(diisopropylamino)ethyl methacrylate) (PDPA) as the hydrophilic block.

[0148] P[(OEG) 10 M.A.] 20 -PDPA 100 , Cy5-P[(OEG) 10 M.A.] 20 -PDPA 100 , Angiopep-P [(OEG) 10 M.A.] 20 -PDPA 100 and PMPC 25 -PDPA 70 The copolymers were synthesized as reported in Tian et al., Sci Rep, 2015, 5, 11990, the contents of which are incorporated herein by reference in their entirety.

[0149] The Angiopep-2 peptide on the polymersome surface targets the LRP-1 receptor, and the PMPC ligand targets the SCARB1 receptor. Approximately 5% of the POEGMA-PDPA chains were labeled with Cy5 dye for fluorescent quantification. Angiopep peptides were conjugated to POEGMA-PDPA copolymers, which were mixed with pristine POEGMA-PDPA at different concentrations. The resulting peptide configurations were expressed on the surface and were attached to the oligoethylene oxide chains (N p PMPC chains were copolymerized with DPA to give PMPC 24 -PDPA 70 were formed and these were mixed with the original POEGMA-PDPA chains at different concentrations.

[0150] To prepare 10 mg / mL polymersomes, the amount of copolymer was weighed and dissolved using PBS at pH 2. Once the film was dissolved, the pH was increased to 5.0. The peptide-functionalized copolymer was then added to avoid acidic degradation. The pH was gradually increased to pH 6.8–7.0 and finally stopped at pH 7.4–7.5. Polymersomes formed during prolonged stirring at pH 6.8–7.0. The polymersomes were then sonicated at 4 °C for 15–30 min. The polymersomes were finally purified by passing them through a gel permeation chromatography column packed with Sepharose 4B (Sigma Aldrich). For long-term storage, the polymersomes can be stored at 4 °C and protected from light when conjugated with dyes. The peptide-functionalized polymersomes were freshly prepared immediately before use. In this regard, it is important to note that although POEGMA-PDPA and PMPC-PDPA chains can undergo phase separation to form patchy polymersomes (see LoPresti et al., ACS Nano, 2011, 5(3), 1775-1784), cell experiments were performed immediately after preparation without allowing sufficient time (3-5 days) for separation.

[0151] The size distribution of polymersomes was measured using dynamic light scattering (DLS) (see Figure 1(a)). The average radius of all formulations was 40 nm (± 10 nm) and the addition of ligands did not change the final structure, as confirmed by both TEM and DLS. Polymersomes were further characterized by transmission electron microscopy (JEOL 2100) using phosphotungstenic acid as a stain and dynamic light scattering (Malvern Nanosizer) (see Figure 1(b)). LRP-1 expression was measured by Western blot (WB) and immunofluorescence (IF). For WB, cells were washed twice with PBS and RIPA buffer (1:50) containing protease inhibitors was added directly to the membrane and left on ice for 1 h. Cells were harvested and centrifuged, and the supernatant was collected for WB analysis. Protein levels in cell lysates were measured using the BCA Protein Assay Kit. Lysates were mixed with Laemmli sample buffer, and proteins (10 μg) were separated on a 10% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. The membrane was blocked with 5% (w / v) nonfat milk in Tris-buffered saline (TBS) containing 0.1% (w / v) Tween 20 (TBS-T) for 1 h and then incubated with rabbit monoclonal antibody against LRP-1 overnight at 4 °C. After washing with TBS-T, the membrane was incubated with secondary antibody for 2 h at room temperature and imaged using an Odyssey CLx (LI-COR Biosciences). The membrane was further probed against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control. IF coronal brain sections were obtained from the animals. Briefly, brain sections were incubated in 20% (v / v) normal horse serum in PBS containing 0.3% (w / v) Triton X-100 for 2 h at room temperature with gentle agitation, then incubated with primary antibody anti-syndapin-2 overnight at 4°C. Sections were washed with PBS, incubated with corresponding secondary antibody and FITC-conjugated lectin (1:200) for 2 h, and washed with PBS. Brain sections were mounted on glass slides in Vectashield Mounting Media.

[0152] Figure 2 shows the results of a control sample of brain endothelial cells and AP 22 Box plot of LRP-1 expression levels in brain endothelial cell samples treated with -POs. A significant increase in LRP-1 expression levels can be observed in cells after treatment with polymersomes.

[0153] In further experiments, brain endothelial cells were 22 Amyloid-β was pretreated with β-POs for 2 h and applied to either the apical (blood) or basolateral (brain) side of cells in a Transwell. Amyloid-β transport from basolateral to apical was then measured for 4 h using Ab40 as a model. Amyloid-β permeability was normalized to untreated cells.

[0154] The results of this experiment are shown in Figure 3. It is noteworthy that AP 22 In cells pretreated with -POs, basolateral to apical transport of amyloid-β was observed with higher levels at the apical rather than basolateral side, suggesting that polymersomes themselves do not directly cause amyloid-β clearance from brain tissue, but instead support an indirect mechanism of action (i.e., elevated polymersome levels at the apical side of cells promote transcytosis and upregulation of LRP-1).

[0155] In this example, each polymersome has 22 Angiopep-2 ligands, λ = 1.1 × 10 -3 , ε B =15k B T, the radius of the polymer is 40 nm, and the surface area is 20.11 × 10 3 nm 2 and the polymersomes were made from POEGMA, which has a molecular weight of δ P = 0.1, which is the V LRP1 =270nm 3 into the POEGMA brush, and σ P -1= 0.08, Γ = 1.5 × 10 -4 (protein / nm 2 ) targets cells expressing LRP-1, which is G = 0.9 and glycocalyx density σ GAG -1 = 0.0088 (glycosaminoglycan (GAG) chain / nm 2 ) corresponds to ζ=3, and the total steric potential u s =11.24k B T. Thus, these polymersomes have the formula ln[(1+λAe) -β(εB+uS)ξ -1] is 20.6, which satisfies the mathematical relationship being explained.

[0156] Example 2: In vivo studies with normal and diseased mice AP synthesized in Example 1 22 -POs were also administered intravenously to mice to monitor the in vivo effects on amyloid-β and tau levels. As a control, the effects on liver and kidney function were also examined. Five different groups of mice (n=3) were utilized in this study:

[0157] [Table 1]

[0158] The Alzheimer's disease model mice are APP-PS1 transgenic AD model mice that have mutations in APP and presenilin-1 (APPswe and PSEN1dE9, respectively), resulting in increased Aβ production. 22 Mice were injected with 18F-POs and sacrificed 1 or 24 h later, and brain and blood Aβ and tau levels were measured by Western blot and ELISA. Also, the brains of mice from groups 1, 3, and 4 were imaged via PET using [18F](E)-4-(2-(6-(2-(2-(2-18F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzamine as a radiolabel.

[0159] Western blots in Figure 4A show that in diseased mice (groups 1-3), both amyloid-β and tau levels in the brain are reduced after polymersome administration, with a pronounced reduction in the levels of these proteins being observed when higher amounts of polymersomes are used. Healthy mice (groups 4 and 5), which show significantly lower starting levels of amyloid-β and tau proteins, also reveal a reduction in the amount of these proteins after polymersome administration. The results are summarized graphically in Figure 4B (amyloid-β levels) and Figure 4C (tau levels).

[0160] Figures 5A-5C show the levels of three liver function markers, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), present in different cohorts of mice. Following treatment of diseased animals with polymersomes (groups 2 and 3), each of these liver function markers is elevated, which was also observed in diseased mice treated with PBS (group 1). This suggests that Alzheimer's disease mice inherently have higher levels of these markers. When healthy mice were treated with polymersomes (group 5), no elevation of liver function markers was observed compared to untreated healthy mice (group 4).

[0161] Figures 6A-6C show the levels of three renal function markers, blood urea nitrogen (BUN), creatine (Cr), and uric acid (UA), present in different cohorts of mice. Similar results were observed in liver function tests. After treatment of diseased animals with polymersomes (groups 2 and 3), each of the renal function markers is elevated, which is also observed in diseased mice treated with PBS (group 1). This suggests that Alzheimer's disease mice inherently have higher levels of these markers. When healthy mice were treated with polymersomes (group 5), no elevation of renal function markers was observed compared to untreated healthy mice (group 4).

[0162] Figure 7 shows the levels of amyloid beta and tau in plasma at various time points after administration of polymersomes to Alzheimer's disease mice group 3. A sharp increase in the plasma concentrations of amyloid beta and tau can be observed immediately after polymersome administration, indicating that amyloid beta and tau have been transported from deposits in the brain into the plasma. The plasma levels of amyloid beta and tau then decrease over time due to clearance.

[0163] Figure 8 shows PET scans of the brains of mice from Group 1 (top), Group 3 (middle), and Group 4 (bottom), which show that the amount of amyloid beta present in the brain is significantly reduced in the polymersome-treated animals compared to diseased animals.

Claims

1. 1. A nanoparticle or microparticle that binds to an endothelial cell surface for use in a method for reducing amyloid-β and / or tau levels in an organ of a patient in need thereof, said nanoparticle or microparticle comprising on its outer surface a ligand species that is capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of said endothelial cells, thereby facilitating transport of LRP-1 across said endothelial cells.

2. The nanoparticle or microparticle for use according to claim 1, wherein the transport of LRP-1 across the endothelial cell occurs via transcytosis, preferably the mechanism of transcytosis involves transport of LRP-1 in a structure stabilized by syndapin-2.

3. 3. The nanoparticle or microparticle for use according to claim 1 or claim 2, wherein said nanoparticle or microparticle comprises 2 to 1000 ligands of said ligand species, preferably 5 to 500 ligands of said ligand species, more preferably 10 to 200 ligands of said ligand species, even more preferably 15 to 100 ligands of said ligand species, most preferably 20 to 50 ligands of said ligand species.

4. The nanoparticle or microparticle for use according to any one of claims 1 to 3, wherein the nanoparticle or microparticle is a polymersome, liposome, synthosome or micelle.

5. The nanoparticle or microparticle for use according to claim 4, wherein the nanoparticle or microparticle is a polymersome.

6. The nanoparticle or microparticle for use according to any one of claims 1 to 5, wherein said nanoparticle or microparticle comprises polymer brushes on its outer surface.

7. The nanoparticles or microparticles have the following relationship: [0010] (In the formula: λ is the density of the ligand species on the outer surface of the microparticle or nanoparticle (nm 2 (number per A is the surface area of ​​the microparticle or nanoparticle (nm 2 ) and ζ=ΓΑ (where Γ is the surface density of the LRP-1 (nm 2 and A is as defined above; β = (k B T) -1 (In the formula, k B is the Boltzmann constant (JK -1 ) and T is absolute temperature (K); ε B is the single energy (J) of binding of the ligand species / LRP-1 receptor pair; and u S is the steric potential (J) between the nanoparticle or microparticle and the cell surface.

7. The nanoparticle or microparticle for use according to any one of claims 1 to 6, wherein the nanoparticle or microparticle comprises the number (λ*A) of ligand species such that:

8. 8. The nanoparticle or microparticle for use according to any one of claims 1 to 7, wherein said nanoparticle or microparticle comprises on its outer surface at least one further ligand species capable of binding to a further receptor species on the cell surface.

9. 9. The nanoparticle or microparticle for use according to claim 8, wherein said nanoparticle or microparticle comprises on its outer surface from 1 to 6 additional ligand species, preferably from 2 to 4 additional ligand species, most preferably 3 additional ligand species, each ligand species being capable of binding to a complementary receptor species on the cell surface.

10. Nanoparticles or microparticles for use according to any one of claims 1 to 9, wherein the ligand species capable of binding to LRP-1 is Angiopep-2.

11. 11. The nanoparticle or microparticle for use according to any one of claims 8 to 10, wherein the at least one further ligand species is capable of binding to a receptor species chosen from scavenger receptor class B, member 1 (SCARB1), transferrin receptor (TFRC), folate receptor 1 (FOLR1) and epidermal growth factor receptor (EGFR).

12. 12. The nanoparticle or microparticle for use according to any one of claims 8 to 11, wherein the at least one further ligand species is selected from poly(2-(methacryloyloxy)ethyl phosphorylcholine), folic acid, transferrin, transferrin mimic peptide, and YHWYGYTPQNVI peptide.

13. 13. The nanoparticle or microparticle for use according to any one of claims 1 to 12, wherein the method is a method for treating or preventing Alzheimer's disease in said patient.

14. The nanoparticle or microparticle for use according to any one of claims 1 to 12, wherein the method is a method for treating or preventing a cerebrovascular disorder in the patient.

15. The nanoparticle or microparticle for use according to any one of claims 1 to 14, further comprising a drug encapsulated within said nanoparticle or microparticle.

16. 16. The nanoparticles or microparticles for use according to claim 15, wherein the drug is selected from anti-Alzheimer's drugs, drugs for treating cerebrovascular disorders, and / or drugs useful for reducing the levels of amyloid-β and / or tau or inhibiting the formation of amyloid-β and / or tau, preferably the drug is selected from donepezil, galantamine, rivastigmine, and memantine.

17. 17. Nanoparticles or microparticles for use according to any one of claims 1 to 16, wherein the polymer brushes comprise poly(ethylene glycol) (PEG), poly(vinylpyrrolidone) (PVP), poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), poly(glycerol), poly(sulfobetaine), poly(carboxybetaine), poly(amino acids), polysarcosine, poly(2-oxazoline), poly(N-(2-hydroxypropyl)methacrylamide), polyglycol, heparin, dextran, poly(ethylene glycol)-poly(2-(diisopropylamino)ethyl methacrylate) and / or poly(oligo(ethylene glycol)methyl ether methacrylate) (POEGMA).

18. 18. The nanoparticle or microparticle for use according to claim 17, wherein the nanoparticle or microparticle comprises on its outer surface a polymer brush comprising poly(ethylene glycol)-poly(2-(diisopropylamino)ethyl methacrylate) and a ligand species capable of binding to LRP-1.

19. 19. The nanoparticle or microparticle for use according to any one of claims 1 to 18, wherein each ligand on the outer surface of the nanoparticle or microparticle is covalently bound to a poly(ethylene glycol) molecule.

20. The nanoparticle or microparticle for use according to any one of claims 1 to 19, wherein the binding of the nanoparticle or microparticle to the endothelial cell surface results in increased expression of LRP-1 in the endothelial cell.

21. The nanoparticles or microparticles for use according to any one of claims 1 to 20, wherein the organ is the brain and the endothelial cells are brain endothelial cells.

22. 22. A pharmaceutical composition for use in a method for reducing amyloid-β and / or tau levels in an organ of a patient in need thereof, said pharmaceutical composition comprising a plurality of nanoparticles or microparticles as defined in any one of claims 1 to 21 and one or more pharma- ceutically acceptable excipients.

23. A method for reducing amyloid-β and / or tau levels in an organ of a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of nanoparticles or microparticles that contain on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of endothelial cells, thereby promoting transport of LRP-1 across said endothelial cells.

24. 24. The method of claim 23, wherein the organ is a brain and the endothelial cells are brain endothelial cells.

25. 1. Use of nanoparticles or microparticles for the manufacture of a medicament for reducing amyloid-β and / or tau levels in an organ of a patient in need thereof, wherein the nanoparticles or microparticles comprise on their outer surface a ligand species capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of endothelial cells, thereby promoting transport of LRP-1 across the endothelial cells.

26. 26. The use according to claim 25, wherein the organ is the brain and the endothelial cells are brain endothelial cells.

27. A nanoparticle or microparticle that binds to an endothelial cell surface, (i) a ligand species on the outer surface of an endothelial cell that is capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on the surface of the endothelial cell, thereby facilitating the transport of LRP-1 across the endothelial cell; and (ii) an encapsulated drug selected from anti-Alzheimer's drugs and / or drugs useful for reducing the levels of amyloid-β and / or tau or inhibiting the formation of amyloid-β and / or tau; wherein preferably the drug is selected from donepezil, galantamine, rivastigmine, and memantine.

28. 28. The nanoparticle or microparticle of claim 27, wherein the endothelial cells are brain endothelial cells.

29. 29. A pharmaceutical composition comprising a plurality of nanoparticles or microparticles according to claim 27 or claim 28, and one or more pharma- ceutically acceptable excipients.